Scholarlink

<p>LINC01123, a long non-coding RNA (lncRNA) encoded on chromosome 2q13, is a crucial regulator in various human cancers. It spans 8,302 nucleotides and is implicated in malignancies like lung, ovarian, colorectal, head and neck, oral, cervical, breast, cholangiocarcinoma, and hepatocellular cancers. LINC01123 acts as a competitive endogenous RNA (ceRNA), sequestering microRNAs such as miR-199a-5p, miR-151a, miR-34c-5p, miR-625-5p, miR-542-3p, and miR-34a-5p to modulate downstream target genes including c-MYC, VEGFA, and AXL. These interactions affect signaling pathways like NOTCH, MAPK, and PI3K-AKT, promoting cancer hallmarks such as cell proliferation, metastasis, angiogenesis, metabolic reprogramming, immune evasion, and radio/chemotherapy resistance. Recent studies suggest LINC01123 also has potential therapeutic roles in vascular and neurological disorders like acute cerebral infarction and venous thromboembolism. Thus, LINC01123 is a promising multi-disease intervention target warranting further exploration of its molecular pathways and clinical applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LINC01123: a pan-cancer “molecular commander” deciphering the CeRNA network atlas for precision diagnosis and therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Zheng Chen,
  • Weijian Zhu,
  • Qiang Yi,
  • Xinting Ouyang,
  • Kui Zhong,
  • Qiong Ge,
  • Mengying Zhang,
  • Qinfu Yan,
  • Jianing Zhong,
  • Jinghua Zhong

摘要

LINC01123, a long non-coding RNA (lncRNA) encoded on chromosome 2q13, is a crucial regulator in various human cancers. It spans 8,302 nucleotides and is implicated in malignancies like lung, ovarian, colorectal, head and neck, oral, cervical, breast, cholangiocarcinoma, and hepatocellular cancers. LINC01123 acts as a competitive endogenous RNA (ceRNA), sequestering microRNAs such as miR-199a-5p, miR-151a, miR-34c-5p, miR-625-5p, miR-542-3p, and miR-34a-5p to modulate downstream target genes including c-MYC, VEGFA, and AXL. These interactions affect signaling pathways like NOTCH, MAPK, and PI3K-AKT, promoting cancer hallmarks such as cell proliferation, metastasis, angiogenesis, metabolic reprogramming, immune evasion, and radio/chemotherapy resistance. Recent studies suggest LINC01123 also has potential therapeutic roles in vascular and neurological disorders like acute cerebral infarction and venous thromboembolism. Thus, LINC01123 is a promising multi-disease intervention target warranting further exploration of its molecular pathways and clinical applications.